Ivermectin Drug Not To Be Included In Centre’s COVID Management Protocol

[-] SwiftJustice88 | 2 points | Oct 22 2020 20:39:38

I’m really not sure what to make of this, would like to hear your opinions. Most of the trials I’ve seen seem very promising!

[-] akaariai | 3 points | Oct 23 2020 04:23:47

Two key points. First, the decision was based on randomized trials in India and aboard. There's not yet many peer reviewed random trials, and as far as I know nothing in India. Second, they didn't say it does not work, they essentially said based on current data they aren't yet sure it works.

So, what they are looking for? If going for the gold standard you want two high quality random trials showing it works. This way you have results and verification of results. India might even want one of the trials done in India.

[-] SwiftJustice88 | 1 points | Oct 23 2020 06:33:44

Thanks so much for explaining, makes sense now!

[-] movethroughit | 1 points | Oct 23 2020 07:03:44

So, what they are looking for? If going for the gold standard you want two high quality random trials showing it works.

If you can get:

The trial approved

The funding

The participants

The right endpoints

Competent personnel

Peer review

All in a timely fashion. So far, the Gold Standard hasn't been a very useful conveyance. I fear we would have to offer up a lot more corpses for its altar.

[-] akaariai | 1 points | Oct 23 2020 07:23:03

Yeah, makes you think if there might be some easier alternative to get the data. Especially for repurposed safe medics it seems a fast path during pandemic for the trials would be a good idea.

Still, there must be reliable data obtained some way. If you go for anecdotes or analysing observational data afterwards only you'll end up curing the disease with frog legs.

[-] movethroughit | 1 points | Oct 23 2020 07:35:08

In the case of Covid, it would seem much would be set right with normalized SPo2 on room air (or a big improvement in that). That shouldn't take long to ascertain, if tested in the early stages. By most accounts, High Dose Melatonin does that and so does IVM. Just that would keep bulk of high risk people out of the hospital and the most expensive part the home kit would be a pulse oximeter.

Can Covid worsen considerably without abnormal SPo2?

[-] movethroughit | 2 points | Oct 23 2020 06:56:06

Uttar Pradesh approved it and they seem to be doing well:

https://www.bing.com/covid/local/uttarpradesh_india?vert=graph

Takes a little time to load. Wait for the bar chart.

[-] ismellcapitalism | 2 points | Oct 23 2020 11:14:49

I continue to be amazed that, for example, US approves Remdesivir officially, though there is NO evidence that it reduces fatalities at all, but won't fund a couple of US randomized controlled trials on ivermectin. However, there are what like 60 studies out there. Looking forward to seeing the Singapore study on transmission; it is closed so they should be publishing data soon. The longer this goes on the more I think it is about money, but not in some diabolical way, but nevertheless nefarious.

[-] massimaux | 2 points | Oct 23 2020 12:31:41

Right on point! Remdesivir approved by FDA despite ineffectiveness shown in the huge (2700 treated + 2700 placebo) trial. Ivermectin is ignored. Smells like public health decisions are driven by interests of big businesses despite the clear evidence on effective and cheap drugs.

[-] Haitchpeasauce | 2 points | Oct 23 2020 13:30:05

RCT of Tocilizumab (an IL6 receptor antagonist) showed no significant improvement in mortality or intubation.

Hydroxycholoroquine, despite my views of its benefit as a zinc ionophore, has enough trial data to indicate it's probably not efficacious for example in this prophylaxis study.

Remdesivir may reduce hospital stays but has no improvement on mortality.

The only effective drug that they have approved is dexamethasone which is for hospital use in later stages of the disease.

ICMR have not approved any early interventions with demonstrated efficacy.

The signal for Ivermectin is much stronger yet they conclude there is insufficient evidence. I am not sure what studies the ICMR’s National Task Force examined, perhaps they don't look at studies from Bangladesh and Argentina?